Trial Profile
A multicenter, open-label, single arm pilot study: Osimertinib as neoadjuvant treatment for resectable stage II-IIIA EGFR mutant lung adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Acronyms NEOS
- 01 Apr 2023 Status changed from recruiting to completed, according to Results published in the Lung Cancer.
- 01 Apr 2023 Results published in the Lung Cancer
- 08 Jun 2021 Status changed to recruiting, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology